Double-digit growth masks sharp profit decline and margin squeeze
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Mid-quarter guidance downgrade (mid-teens PBT → double-digit); Q1 revenue bottom-end, PAT sharply negative; Crop Care recovery deferred to Q2-end; margin pressure in Oil Palm and Dairy vs. sales growth.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered at low end of guidance (9.2% revenue, -13.8% PAT) with management downgrading consolidated PBT target from mid-teens to double-digit. Animal Nutrition and Oil Palm remain solid; Astec recovering. But Crop Care miss (−16.2%), dairy margin pressure, and oil palm margin compression (19%→17% despite higher realizations) signal operational stress. Long-term drivers (Oil Palm scale-up to 150k hectares, Godrej Foods B2C target 65-70%) are credible but lack near-term visibility.
₹2855.2 Cr
Revenue · +9.2% YoY₹128.3 Cr
Reported PAT · −13.8% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
10% YoY consolidated growth despite challenging environment
OVERSTATED9.2% YoY revenue growth; below prior early double-digit FY27 target
Strong Animal Nutrition quarter with 12.6% revenue and 29% segment profit growth
METCattle feed 15%, overall segment 12.6%; reported EBITDA per tonne ₹2,100-2,150, above guidance
Oil Palm momentum with 28.9% revenue growth and 14.4% profit growth
MixedRevenue growth confirmed 28.9%; segment result up 14.4%; but margins fell 19% → 17% YoY despite higher CPO realizations (+18%)
Mid-teens PBT growth guidance for FY27 achievable
MISSQ1 PAT down 13.8% YoY; guidance now stated as double-digit (not mid-teens); flagged Crop Care recovery uncertain until Q2-end
Astec at EBITDA breakeven vs ₹11 Cr loss prior year
METConfirmed; upgraded full-year revenue guidance to 20%+ (prior 20%); CDMO margins intact
Crop Care recovery expected from Q2 given soft Q1 base
PartialQ1 revenue down 16.2%; management deferred call on FY recovery to Q2-end; cited June 40% rainfall deficit, new product ramp (Ashitaka 18-20% of Q1, Takai early-stage)
Dairy (CDPL) strong with 11.4% revenue growth and value-added products momentum
OVERSTATEDRevenue growth 11.4% confirmed; but profitability impacted by elevated milk procurement costs and packaging inflation from geopolitical disruptions; management passing only 70% of cost increases through
Earnings quality
What changed since the last call
Consolidated PBT growth guidance downgraded
DowngradePrior: mid-teens PBT growth FY27. Now: double-digit growth (management stated 'still pretty confident of double-digit'). Q1 PAT −13.8% YoY; full-year visibility uncertain pending Crop Care.
Astec FY27 revenue guidance upgraded slightly
UpgradePrior: 20%. Now: 'at least 20%+' (modest upgrade). Q1 revenue moderately lower but EBITDA improved to breakeven from −₹11 Cr loss. CDMO dissidence 50-52% FY27.
Crop Care H2 recovery uncertain; Ashitaka contribution raised
NeutralQ1 down 16.2% due to monsoon miss. Ashitaka/Takai contributing 18-20% of Q1 Crop Care sales (new products scaling). Management deferred FY outlook to Q2-end given 'sketchy' cotton herbicide season visibility.
Oil Palm margin profile clarified as seasonal, not structural
NeutralSegment margin fell 19%→17% despite +18% CPO realization and improved OER (18.4%→18.8%). Management attributed to 'formula pricing' and FFB seasonality. Expects recovery in peak H2 seasons.
Dairy (CDPL) route-to-market transformation underway; profitability under pressure
DowngradeCDPL saw 8% volume growth (+11.5% value) but profitability hit by milk procurement inflation (+4 qtrs) and packaging costs. Management launching 18-20 month route-to-market overhaul; expects recovery via value-added mix and cost initiatives.
The Q&A
Moderate pushback, mostly answered. Analysts pressed on Crop Care weakness (Abhijit, Vanshika, Hardik) vs. peers; Sunil attributed to segment composition, not execution. Oil Palm margin decline probed (Vanshika, Arun); management blamed formula pricing and seasonality. Dairy pains questioned (Probal); management extensive but acknowledged milk cost and packaging inflation. No analyst forced management to withdraw or restate prior guidance explicitly; management softened mid-teens PBT target verbally but didn't flag a formal cut.
Oil Palm expansion & EBITDA — Abhijit Akella, KIE
AnsweredFFB target high single-digit to early double-digit growth (4-5yr LRP). Area expand 80k→150k hectares (17k acres added last yr); juvenile 50%, maturing 4-8yr peak. Specialty fats facility (Sep launch) expected to add ~200 bps EBITDA margin when scaled. Capex ₹300-350 Cr at 16-18% IRR.
Crop Care recovery prospects — Abhijit Akella, KIE
PartialQ1 hit by June 40% rainfall deficit. Ashitaka/Takai/ Ghassnash new product launches ramping (18-20% Q1 Crop Care sales). July better than prior year. Will call recovery by Q2-end. Astec 20%+ FY growth confirmed. Overall PBT target 'double-digit still' (softened from mid-teens).
Animal feed commodity hedging — Vanshika Jain, Aequitas
AnsweredPassed 60-70% cost to market; cattle feed +15%, fish +20%. EBIT/tonne guidance ₹2,050-2,150 maintained (slightly higher this Q). Strategic sourcing navigated commodity volatility; premium feed demand boosted by high milk prices.
Oil Palm margin decline — Vanshika Jain, Aequitas; Arun, Unifi Capital
AnsweredGovernment pricing formula changes; FFB volumes flat (seasonal: prior yr early monsoon). OER held stable (18.4%-18.8%). Expects recovery in peak H2 seasons; Q1 one-off. Specialty fats will help.
Dairy (CDPL) pricing & transformation — Probal Sen, ICICI Securities
AnsweredMilk costs elevated 4 qtrs; passing 70% through pricing. Packaging inflation (geopolitical) expected to ease by Aug. Launching 18-20mo route-to-market overhaul under new CEO Gaurav. Pressing value-added mix (salience 42%→49%). Focus on cost initiatives & growth.
Godrej Foods B2C scale & strategy — Probal Sen, ICICI Securities
AnsweredStrategic shift: live-bird down 15-20% planned over 3-4yr; B2C (Yummiez + Real Good) growing 28% volumes, 20%+ value. Targeting 65-70% B2C salience over LRP. Investment phase in automation, NPD (momos, frozen chicken). Current 32% salience.
Astec CDMO order pipeline — Abhijit Akella, KIE
AnsweredUpgraded to 20%+. CDMO margins intact, higher than enterprise. Some H1→H2 shift in customer demand; dissidence 50-52% FY27. Q1 revenue moderately lower but EBITDA improved to breakeven.
Animal Nutrition portfolio & non-cattle verticals — Arun, Unifi Capital
AnsweredConscious strategy: exiting unprofitable poultry geographies. Fish feed +20%, swine growing. Cattle 55-56% of segment; fish 7%. Overall 7% vol growth reflects mix shift away from low-margin poultry.
Crop Care new products contribution & margin — Vanshika Jain, Aequitas
AnsweredAshitaka/Takai combined 18-20% of Q1 Crop Care sales. Margins lower than Hitweed (in-license vs in-house) but healthy. Scale benefits & cost leverage expected as products mature.
Crop Care underperformance vs industry peers — Hardik Solanki, ICICI Securities
PartialMacro (June 40% rainfall deficit) hitting cotton herbicide (concentrated segment). Peers have different portfolio. Company diversifying (Ashitaka maize, Takai paddy, Ghassnash soybean). No execution miss vs peers—macro & portfolio-specific.
Guidance
FY27 consolidated double-digit revenue growth (prior early double-digit, maintained but lower tone)
MediumQ1 at 9.2% YoY; management stated 'still pretty confident of double-digit growth still' but flagged Crop Care uncertainty until Q2-end. Implies FY27 revenue ~₹11,300-11,600 Cr (8-10% CAGR baseline + segments).
Oil Palm FFB volume high single-digit to early double-digit (4-5yr LRP, conservative target double-digit)
MediumDriven by 80k→150k hectare expansion, geographic diversification (Telangana, NE), demographic dividend (50% juvenile maturing), OER efficiencies. Phased over next 4-5 years.
Astec revenue growth at least 20%+ FY27 (prior 20%, upgraded)
MediumQ1 revenue moderately lower but EBITDA breakeven achieved. CDMO dissidence 50-52% FY27. H1→H2 order timing shift noted; orders intact.
Oil Palm segment margin recovery H2 FY27; 200 bps EBITDA uplift from specialty fats when fully scaled (multi-year)
MediumQ1 margin fell 19%→17% due to formula pricing & FFB seasonality. Expects peak H2 seasons, factory scale efficiencies, specialty fats early ramp to recover. Full impact multi-year post-scaling.
Animal Nutrition EBIT/tonne ₹2,050-2,150 guidance maintained (slightly higher Q1 delivery)
HighNavigated commodity volatility via strategic sourcing (60-70% pass-through); premium feed demand from high milk prices. Expecting structural benefits to continue.
Dairy (CDPL) profitability under pressure H1; cost initiatives & value-added mix to drive H2 recovery
LowMilk procurement costs elevated 4 qtrs; packaging inflation one-off (expect ease by Aug). Route-to-market transformation ongoing (18-20 mo). Margin recovery multi-quarter dependent on execution.
Godrej Foods B2C to reach 65-70% salience over LRP; operating in investment phase (EBITDA + advertising)
MediumCurrently 32% salience. B2C growing 28% volume, 20%+ value. Investments in NPD, automation, advertising ongoing. Full margin benefit 3-4 years post-peak scale.
FY27 capex ₹300-350 Cr (refined from ₹350-400 Cr prior); focused on Oil Palm value-addition & high-growth areas
HighKey investments: Oil Palm integrated complex (Kannan CPO mill + nursery + seed garden + refinery phased), specialty fats refinery (Sep 2026), Godrej Foods plant automation. All assumed in guidance; no new investment.
Risks the call surfaced
Monsoon/weather volatility
HighQ1 June 40% rainfall deficit hit Crop Care (−16.2% revenue) and constrained Oil Palm FFB (flat YoY despite improved practices). Monsoon erratic through Q2; Crop Care recovery call deferred to Q2-end.
Input cost inflation (milk, packaging)
HighDairy milk procurement elevated 4 quarters; packaging costs spiked from geopolitical disruptions (LPG→crude oil→packaging). Management passing only 70% through pricing; profitability impacted.
Crop Care execution risk
MediumNew product launches (Ashitaka maize, Takai paddy, Ghassnash soybean) targeting 18-20% of Q1 Crop Care sales; full-year contribution uncertain. Company betting on diversification away from cotton herbicide (weather-sensitive, historically concentrated). Recovery outlook unclear until Q2-end.
Oil Palm margin pressure (formula pricing)
MediumSegment result +14.4% (revenue +28.9%); margin fell 19%→17% YoY. Attributed to government formula pricing changes & FFB seasonality. CPO realizations +18%, but gains passed to farmers/suppliers.
Guidance downgrade (mid-teens PBT → double-digit)
HighPrior FY26-call guidance was 'mid-teens PBT growth' for FY27. Management now states 'double-digit growth still' pending Crop Care recovery (Q2-end call). Q1 PAT −13.8% YoY; full-year PBT achievement now at risk.
Management
Score 6/10. Verbose and explanatory; lengthy Q&A responses (sometimes repetitive across questions). Transparent on challenges (monsoon miss, input inflation, margin pressure) but defensive on guidance changes. Evasive on specific Crop Care recovery timelines ('by end of September'). Strategic narrative clear (Oil Palm scale, Foods B2C, Astec recovery) but lacks quantified FY27/28 PAT targets beyond Astec. Mixed track record. Animal Nutrition and Oil Palm volume targets on track. Astec recovery achieved (breakeven vs −₹11 Cr loss). But Crop Care missed expectations (−16.2% vs prior recovery narrative), Dairy profitability hit (milk cost inflation), Oil Palm margins compressed (formula pricing). Prior mid-teens PBT guidance now softened to double-digit.
1 · Q2 FY27 (Sep 2026)
Crop Care recovery clarity; cotton herbicide season assessment; monsoon impact full-half visibility
2 · H2 FY27 (Oct-Mar 2027)
Oil Palm specialty fats refinery ramp-up (Sep early launch); Ashitaka/Takai scale-up; Godrej Foods B2C NPD pipeline impact
3 · FY27-end (Mar 2027)
Full-year PBT growth outcome vs. double-digit target; guidance reset for FY28 multi-digit growth trajectory
Long-term drivers (Oil Palm scale-up to 150k hectares, Godrej Foods B2C target 65-70%) are credible but lack near-term visibility.
Revenue Growth Masks Profit Collapse and a Quiet Guidance Cut
Godrej Agrovet reported 9.2% revenue growth but profit fell 13.8% YoY. Management downgraded full-year guidance from mid-teens PBT growth to double-digit. The market got it right — the stock fell on day 1 and held its loss.
₹2,855 Cr
+9.2% YoY
₹128 Cr
-13.8% YoY
4.5%
Below historical range
8.4%
Compressed
The headline reads like growth — nearly 10% revenue expansion — but the profit story tells a different truth. Net profit fell 13.8% despite revenue rising 9.2%. That gap, and the market's reaction to it, is the quarter in a single frame.
The tension: top line up, bottom line down
Margins compressed across the board. Operating profit margin fell to 8.4% from implied higher range. The culprits: Crop Care weather miss (−16.2% revenue), Dairy milk procurement inflation (₹11.4% revenue growth but profitability hit), Godrej Foods live-bird degrowth and geopolitical packaging cost spikes. Animal Nutrition and Oil Palm grew volumes, but Oil Palm's margin fell from 19% to 17% despite CPO realizations up 18% — management attributed this to government formula-pricing changes and FFB seasonality, but the fact remains: segment result growth (14.4%) lagged revenue growth (28.9%).
What management claimed vs. what holds up
10% YoY consolidated growth despite challenging environment
Actual: 9.2% YoY revenue growth; below early double-digit FY27 target
Strong Animal Nutrition quarter with 12.6% revenue and 29% segment profit growth
Confirmed. Cattle feed +15%, EBIT/tonne ₹2,050–2,150 held guidance
Oil Palm momentum with 28.9% revenue and 14.4% profit growth
Mixed. Margins fell 19% → 17% YoY despite +18% CPO realizations
Mid-teens PBT growth guidance for FY27 achievable
Contradicted. Q1 PAT −13.8% YoY; guidance now double-digit (not mid-teens)
Crop Care recovery expected from Q2 given soft Q1 base
Partial. Management deferred call to Q2-end; June 40% rainfall deficit cited
What changed on this call
Guidance downgraded (not formally stated as a cut, but clearly softened): prior mid-teens PBT growth guidance now restated as 'double-digit still' pending Crop Care recovery. Astec upgraded slightly to '20%+' (from 20%) after achieving EBITDA breakeven vs. −₹11 Cr loss prior year. Crop Care recovery deferred to end of Q2 (September) given June rainfall deficit; Ashitaka and Takai new-product contribution (18–20% of Q1 segment sales) is ramping but uncertain. Oil Palm margins clarified as seasonal, not structural — management expects recovery in peak H2 seasons and cites formula-pricing headwinds. Dairy route-to-market transformation launched under new CEO Gaurav, 18–20 month horizon, targeting value-added mix increase (currently 42%, target 49%) to offset milk procurement and packaging cost inflation.
The market's verdict and positioning
The stock fell 3.69% on day 1 post-result (from ₹566.45 to below ₹545) and held its loss through day 5 (−2.85% cumulative). This was the correct read. Revenue of 9.2% YoY misses the prior 'early double-digit' FY27 target, PAT collapsed despite that growth, and guidance was quietly cut. The market did not forgive the miss. At ₹580.5, the stock is now 13.85% below its all-time high of ₹673.8 and trading slightly above its SMA20 (₹563) and SMA50 (₹564.6), but has recovered modestly off the day-1 low. RSI at 52.6 signals neutral momentum. Institutional flows are mixed: FII marginally added +0.16pp to 6.48% (net positive but small), DII trimmed −0.58pp to 5.28% (net negative), promoter holding flat at 67.74%. The FII move is mild — not a vote of confidence, more a steady-hands observation. The DII trim is more telling: domestic institutions are not excited.
Bull-bear ledger
Animal Nutrition: +12.6% revenue, +29% segment profit, EBIT/tonne +15% holding
Oil Palm volume target tracking (80k → 150k hectare plan on pace); OER stable
Astec stabilized: EBITDA breakeven vs. −₹11 Cr loss; CDMO margins intact
Godrej Foods B2C growth +28% volume, +20% value; long-term 65–70% salience clear
PAT −13.8% despite revenue +9.2%; margin compression across segments
Crop Care −16.2% revenue; recovery deferred to Q2-end (Q2 monsoon risk)
Oil Palm margin fell 19% → 17% despite +18% CPO realizations (formula pricing hit)
Dairy profitability pressured; only 70% cost pass-through; milk inflation expected 2–3 qtrs more
Guidance quietly cut mid-teens PBT → double-digit; not formally reset (credibility issue)
FII adding marginally, DII trimming; no institutional conviction
Risks, ranked by how much they should concern a holder
Crop Care recovery uncertain until Q2-end; June 40% monsoon deficit repeats in H2
HIGHCrop Care is down 16.2% Q1. If July/August/September also see erratic monsoon, the easy-base narrative fails. Company defers full-year clarity to September, implying low visibility. Monsoon is also headwind for Oil Palm FFB.
Guidance downgraded without formal reset; management credibility dented
HIGHMid-teens PBT target was public. Now restated as 'double-digit still.' No explicit cut, no restatement in official channels, but the softening is undeniable. If Q2/Q3 misses also come, investors will question whether management is withholding bad news.
Oil Palm margin compression persists (19% → 17%); formula pricing risk ongoing
MEDIUMSegment result growth (14.4%) lagged revenue growth (28.9%). Management attributes to government formula changes and seasonality, but if formula pricing is structural (not one-off), the high-growth segment becomes lower-margin. Specialty fats refinery (Sep 2026 launch) is expected to add 200 bps EBITDA margin, but this is multi-year and subject to execution.
Dairy (CDPL) profitability recovery delayed 2–3 qtrs minimum; milk inflation persistent
MEDIUMMilk procurement elevated for 4 consecutive quarters. Management says 'likely 2–3 more quarters' of impact. CDPL is passing only 70% of cost increases through pricing. Route-to-market transformation is 18–20 months. Near-term margin recovery is not assured.
Godrej Foods B2C investment phase masks live-bird degrowth (−15–20% planned)
LOWB2C is growing 28% volume, 20%+ value, but this offsets planned live-bird contraction. If B2C growth falters or margins disappoint, the segment's overall profitability could surprise to the downside. Currently 32% of mix, targeting 65–70%; long-term bet, not assured.
Astec demand timing: H1 → H2 shift in CDMO orders may front-load H2 uncertainty
LOWQ1 Astec revenue moderately lower due to product mix shift and order timing. FY27 guidance upgraded to 20%+, but this assumes H2 order catch-up. If CDMO customer orders slip further, Astec's upgrade is at risk.
What to watch next
1 · Crop Care recovery call (Q2-end, expected September 2026)
Management will provide full-year Crop Care outlook by Q2-end. If July/August monsoon improves and Ashitaka/Takai ramp as expected, the easy-base narrative re-enters. If monsoon remains erratic or new-product adoption disappoints, FY27 revenue growth will miss. This is the single largest earnings swing.
2 · Oil Palm specialty fats refinery ramp (scheduled Sep 2026 early launch)
The refinery is expected to add 200 bps EBITDA margin when scaled, addressing the segment's margin compression. Early ramp success will validate management's 'seasonality, not structural' claim on the 19% → 17% margin fall. Delay or margin miss would extend the downside.
3 · Dairy (CDPL) route-to-market overhaul early wins (18–20 month timeline)
New CEO Gaurav is launching a transformation targeting value-added mix (currently 42%, target 49%) and cost initiatives. If Q2/Q3 show early traction in value-added penetration and milk-cost leverage, confidence in FY27 profitability recovery rises. Silence or slippage extends the margin-pressure narrative into FY28.
The honest read
Godrej Agrovet is not broken — it's in transition. Animal Nutrition is working, Oil Palm volume plan is on track, Astec has turned, and Godrej Foods B2C is ramping credibly. But the company is absorbing multiple near-term headwinds (monsoon, input costs, formula pricing) simultaneously and has sacrificed 2–3 quarters of earnings to reposition the portfolio. The issue is not strategy; it is execution credibility and near-term visibility. Management downgraded guidance without owning the downgrade, Crop Care recovery is deferred to Q2-end (a full quarter of uncertainty), and Dairy margin recovery is 2–3 qtrs away. The market correctly punished day 1 and held its loss. DII is trimming.
The single number to track
Q2 PAT growth (YoY). If Q2 PAT is flat to up low-single-digit YoY, the earnings trough is likely Q1 and the recovery narrative is live. If Q2 PAT is also down double-digit YoY, the guidance miss is systemic, not cyclical, and the stock re-rates lower. This is a show-me moment.
Hold. The long-term drivers are real, but execution on near-term catalysts is the prerequisite. Revisit on Crop Care recovery call and Q2 PAT delivery.
Godrej Agrovet Q1 FY27: consol. PAT -14% YoY as margins compress, Crop Care still weak
PAT -13.8% YoY · revenue +9.2% · margins compressing
₹2,855.22 Cr
+9.2% YoY
₹128.31 Cr
-13.8% YoY
4.47%
-1.2pp YoY
₹6.99
Godrej Agrovet's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 9.2% YoY to ₹2,855.22 Cr, but consolidated PAT ("profit for the period") fell 13.8% YoY to ₹128.31 Cr (EPS ₹6.99 vs ₹8.35 a year ago), even as it rebounded 25.4% QoQ from a seasonally soft Q4 FY26 base of ₹102.28 Cr — that sequential jump reflects the return of the Q1 kharif-season pickup in an agri-linked business rather than a structural improvement, and should not be read as trend confirmation. Consolidated PBT (before exceptional items, including share of JV profit) fell 9.7% YoY to ₹181.13 Cr. Neither this quarter nor the year-ago quarter carried any exceptional items at the consolidated level, so the decline is entirely operating in nature.
Q1 FY-2027 vs prior quarters
The compression sits on operating margin: OPM eased to 8.41% from 10.32% a year ago (though up sequentially from Q4's seasonal low of 5.96%), while NPM fell to 4.49% from 5.69%. By segment, Crop Care Business (which houses Astec Lifesciences' agrochemical/CDMO operations) was the primary drag — revenue fell 13.3% YoY to ₹349.02 Cr and segment PBIT dropped 35.1% YoY to ₹75.55 Cr. Poultry & processed food PBIT collapsed 80.5% YoY to ₹0.87 Cr, and Dairy swung to a small segment loss of ₹(1.90) Cr from a ₹4.31 Cr profit despite 11.5% revenue growth. Offsetting this, Animal Nutrition (+12.6% revenue, +29.7% PBIT YoY) and the Vegetable Oil/Oil Palm business (+24.1% revenue, +14.7% PBIT YoY) delivered the momentum management had flagged — the latter coinciding with the inauguration of India's first integrated Oil Palm complex on July 20, 2026.
The stock went into the print at ₹566.95, up 1.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
Management guides for early double-digit consolidated revenue growth in FY'27, driven primarily by volume, accompanied by mid-teens PBT growth. This outlook is supported by continued momentum in the Animal Nutrition and Oil Palm businesses, a strong recovery expected in Crop Care from Q2, and a continued turnaround in
— This quarter: missed
Against management's own guidance from the Q4 FY26 call — early double-digit consolidated revenue growth and mid-teens PBT growth for FY27, with Crop Care recovery expected only from Q2 and a continued Astec CDMO-led turnaround — Q1's 9.2% revenue growth trails the "early double-digit" mark, and PBT declined rather than growing mid-teens, a clear miss on pace even though management had itself signalled that Crop Care weakness would persist through Q1. No management press release accompanied this filing, so there is no company framing to cross-check against the numbers, and no reliable Street consensus estimates for this specific quarter turned up in public previews, so the print cannot be benchmarked against consensus. Standalone PAT, by contrast, rose 8.7% YoY to ₹183.60 Cr — the divergence from consolidated (>3%) owes mainly to a ₹49.7 Cr JV dividend booked at the standalone level (eliminated on consolidation) and to weaker subsidiary-level performance (Astec, Crop Care, Poultry) that only shows up post-consolidation. Separately, the company disclosed a CFO transition alongside results: S. Varadaraj will take early superannuation effective September 30, 2026, with Ravishankar A. (previously VP-Finance at HUL's Beauty & Wellbeing business) named incoming CFO from October 1, 2026, with no stated link to the quarter's performance. This sets up Q2 FY27 as the checkpoint for the guided Crop Care recovery and for whether full-year PBT growth can still close the gap to the guided mid-teens pace after a Q1 shortfall.
W1
Crop Care recovery — management guided a 'strong recovery from Q2 FY27' after segment PBIT fell to ₹75.55 Cr (-35.1% YoY) in Q1; watch the Q2 print against this promise.
W2
Full-year PBT guidance of mid-teens growth needs to be made up after Q1 consolidated PBT fell 9.7% YoY to ₹181.13 Cr — watch for H2 acceleration.
W3
CFO handover on October 1, 2026 (Ravishankar A. succeeding S. Varadaraj) — watch for continuity in reporting and guidance through the transition.
Consolidated 'profit for the period' of ₹128.31 Cr includes a non-controlling interest loss of ₹(6.19) Cr, so owners' share was higher at ₹134.50 Cr (mainly Astec/Creamline minority stakes). Standalone other income includes a ₹49.7 Cr JV dividend eliminated on consolidation. No exceptional items in either statement for Q1 FY27 or the year-ago quarter, so YoY moves are purely operating.